Esperion Therapeutics DEF 14A: Executive Pay Details
Ticker: ESPR · Form: DEF 14A · Filed: Apr 17, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | DEF 14A |
| Filed Date | Apr 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, governance
TL;DR
Esperion's 2024 exec pay is out. Check the DEF 14A for Koenig & Mayleben's compensation details.
AI Summary
Esperion Therapeutics, Inc. filed its DEF 14A on April 17, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on compensation for key executives such as Mr. Koenig and Mr. Timothy Mayleben, with compensation components like equity awards and adjustments. The company's principal executive offices are located at 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108.
Why It Matters
This filing provides transparency into how Esperion Therapeutics compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures of executive compensation, but significant changes or unusually high compensation can signal potential governance or financial risks.
Key Numbers
- 2024 — Fiscal Year End (The period for which executive compensation is reported.)
- 20250417 — Filing Date (The date Esperion Therapeutics filed this DEF 14A.)
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Filer of the DEF 14A
- Mr. Koenig (person) — Executive compensated
- Mr. Timothy Mayleben (person) — Executive compensated
- 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108 (location) — Company's business address
FAQ
What is the total compensation for Mr. Koenig for the fiscal year 2024?
The filing indicates compensation details for Mr. Koenig for the fiscal year 2024, but specific dollar amounts are not provided in this excerpt.
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders for an upcoming annual meeting or special meeting of shareholders.
When was Esperion Therapeutics, Inc. formerly known as HDL THERAPEUTICS INC?
The company's name changed from HDL THERAPEUTICS INC on May 13, 2008.
What is Esperion Therapeutics' Standard Industrial Classification (SIC) code?
Esperion Therapeutics' SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the business phone number for Esperion Therapeutics?
The business phone number listed for Esperion Therapeutics is 734-887-3903.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 17, 2025 by Mr. Koenig regarding Esperion Therapeutics, Inc. (ESPR).